$25,000 Match
Home | News | Events | Press | Contact  

About UseNewsletterMessage BoardsAction CenterAdvocateWalk to End Alzheimer’sShopDonate

Find your chapter:

search by state

Parkinson's Disease
Text Size controlsNormal font sizeMedium font sizeLarge font size

Key features

  • Parkinson’s is classified chiefly as a movement disorder, with hallmark symptoms including tremors and shakiness, stiffness, difficulty with walking and muscle control, lack of facial expression and impaired speech.

  • Many individuals with Parkinson’s develop dementia in later stages of the disease.


The FDA has approved rivastigmine (Exelon), a cholinesterase inhibitor, to treat mild-to-moderate dementia associated with Parkinson’s disease. Other cholinesterase inhibitors may receive similar approval in the future.

Pathological substrate

Parkinson’s is another disease, in addition to dementia with Lewy bodies, in which Lewy bodies are found in the brain. The disease causes extensive loss of certain neurons in a brain region called the substantia nigra. This region also experiences gliosis, or the proliferation of helper cells called astrocytes in areas where neurons once existed.

For your patients and families: Parkinson’s Disease Dementia


Sign up for our e-newsletter

Stay up-to-date on the latest news and advances in Alzheimer's treatments, care and research. Get tips for living with Alzheimer's as well as simple ideas on how you can support the fight to end Alzheimer's.

First name: Last name:

*Email: *Zip:

The Alzheimer's Association does not share e-mail addresses with third parties. Please read our security and privacy policy.

Alzheimer's Association

Our vision is a world without Alzheimer's
Formed in 1980, the Alzheimer's Association is the world's leading voluntary health organization in Alzheimer's care, support and research.